Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

08.

"During the past year we have maintained a strong cash position and continued to advance our product development programs despite the global financial turmoil," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Over the next twelve months, we will continue to execute on our strategy to build a sustainable business through investment in the acquisition and development of innovative products that deliver significant value to patients, customers and our shareholders."

Total revenue for the fourth quarter of fiscal year 2009 was $4,594,000 compared to $3,301,000 for the same period in fiscal year 2008, an increase of 39%. Operating expenses for the fourth quarter of fiscal year 2009 were $7,809,000, compared to $7,165,000 for the same period in fiscal year 2008. Net loss for the fourth quarter 2009 was $2,693,000 or $0.09 per diluted share compared to a net loss of $3,198,000 or $0.10 per diluted share in the same period in fiscal year 2008.

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 in combination with magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 30 clinical sites within the U.S. and Canada and will enroll approximately 250 patients. We have made steady progress on enrollment and plan to complete this trial by the end of the year. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet med
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015  Resolution Bioscience announced today the successful results ... TM , a blood-based liquid biopsy for an ALK-gene fusion ... the most common form of this cancer. Researchers or ... to personalized therapies and direct them into clinical trials ... of Health, the CLIA authority in Washington ...
(Date:5/20/2015)... Carolina , 20. Mai 2015 ... für klinische Logistik (Clinical Logistics Organization/CLO) ... Geschäftsjahr 2014, das am 31. Dezember ... Unternehmen hat die Marktentwicklung übertroffen und ... - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... NC (PRWEB) May 20, 2015 ... NC based not-for-profit organization, is pleased to announce they ... Clinical Trials Day. These donations represent the effort and ... study at the GGI partner sites in 2014. ... highlight the greater good of clinical trial participation, GGI ...
(Date:5/20/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCSD), ... present data from ongoing clinical and preclinical studies ... Approaches to Cancer Immunotherapy. OncoSec,s Chief Scientific Officer ... Medical Officer Mai. H. Le, MD, will present ... Can Increase CD8 TILs and Drive Systemic Anti-Tumor ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 3OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 4
... Biotechnology Corporation (the "Company") ( www.generex.com ) (OTC Bulletin ... entered into a securities purchase agreement with certain institutional ... to purchase up to $6 million of shares of ... of common stock.  At the initial closing, the investors ...
... Jan. 24, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio ... " Company"), a leading China-based biotechnology company focused ... today announced that it has received official notification ... granting 3SBio manufacturing approval for a TPIAO label ...
... 24, 2011 Spherix Incorporated (Nasdaq: ... in diabetes, metabolic syndrome and atherosclerosis; and providers of ... and pharmaceutical companies, today announced the closing of previously ... its common stock and warrants to purchase shares of ...
Cached Biology Technology:Generex Announces $3.0 Million Capital Investment 2Generex Announces $3.0 Million Capital Investment 3Generex Announces $3.0 Million Capital Investment 43SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP 23SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP 33SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP 4Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants 2Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants 3
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... To help conserve one of Earth,s ecological treasures, The ... to dramatically improve the management and sustainable use of ... of intact forest in the world. In collaboration ... Service, the Botanical Garden is committing its expertise in ...
... FL--In Florida, where population growth, drought, and saltwater intrusion ... effective ways to educate consumers about household water use ... Florida was included on the Natural Resources Defense Council,s ... shortages in the coming years; the daily total state ...
... State University, in collaboration with Michigan State University, has identified ... the workers. The scientists unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "The gene ...
Cached Biology News:NYBG launches Amazon Forest Program to help conserve Earth's largest intact forest 2NYBG launches Amazon Forest Program to help conserve Earth's largest intact forest 3NYBG launches Amazon Forest Program to help conserve Earth's largest intact forest 4NYBG launches Amazon Forest Program to help conserve Earth's largest intact forest 5NYBG launches Amazon Forest Program to help conserve Earth's largest intact forest 6Can workshops on household water use impact consumer behavior? 2Research led by Wayne State discovers single gene in bees separating queens from workers 2
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... The benchmark for analytical performance ... ease-of-use and the ultimate in ... Varian 810-MS features include: ... optics minimize,interferences, providing reliable, routine, ...
... liter of urine will give a positive reaction ... ,Certification: The Donors are of US origin ... NEGATIVE for HbsAg, HCV, HIV-1 & 2, Syphilis ... THIS MATERIAL IS SOLD FOR IN-VITRO DIAGNOSTIC USE ...
... The LUMIstar OPTIMA is a ... is designed for the widest possible ... labels: Reporter gene assays luciferase, ... (luminol, acridinium esters, dioxetanes..) Luminescent ...
Biology Products: